武汉地区34家医院2011-2013年抗病毒药物应用分析

发布时间：2018-09-11 18:10

【摘要】：目的:为临床合理使用抗病毒药物提供参考。方法:采用回顾性方法,对武汉地区2011-2013年34家医院抗病毒药物的销售金额、用药频度(DDDs)和日均费用(DDC)进行统计和分析。结果:2011-2013年间武汉地区多数抗病毒药物年销售金额和DDDs逐年上升。销售金额稳居前5位的是恩替卡韦、阿德福韦酯、拉米夫定、替比夫定、更昔洛韦;DDDs稳居前5位的为阿德福韦酯、恩替卡韦、替比夫定、拉米夫定、三氮唑核苷,其中恩替卡韦销售金额在2013年占比最高,达43.33%,且其DDDs增长最快。奥司他韦2013年销售金额猛增,约为2012年的18倍,其DDDs亦增长迅速;而穿琥宁的销售金额、DDDs明显下降。多数药物的DDC趋于稳定,但穿琥宁和奥司他韦的DDC波动较大。结论:武汉地区2011-2013年抗病毒药物的使用相对稳定,抗肝炎病毒的核苷类等西药占据抗病毒药主要市场。恩替卡韦的销售金额和DDDs增长迅速,而穿琥宁注射液的应用明显下降。
[Abstract]:Objective: to provide reference for rational use of antiviral drugs in clinic. Methods: the sales sum of antiviral drugs, drug frequency (DDDs) and daily average cost (DDC) in 34 hospitals in Wuhan from 2011 to 2013 were analyzed retrospectively. Results the annual sales and DDDs of most antiviral drugs in Wuhan increased year by year. Among the top 5 steady sales figures were entecavir, adefovir, lamivudine, tibivudine, ganciclovir, DDDs, adefovir, entecavir, tibivudine, lamivudine, triazolonucleoside, Entecavir accounted for the highest share of sales in 2013, at 43.33, and its DDDs grew fastest. Sales of oseltamivir surged in 2013 to about 18 times that of 2012, and its DDDs also grew rapidly, while that of Chuanhuning fell significantly. The DDC of most drugs tended to stabilize, but the DDC of Chuanhuning and oseltamivir fluctuated greatly. Conclusion: the use of antiviral drugs in Wuhan from 2011 to 2013 is relatively stable, and antiviral nucleosides and other western drugs occupy the main market of antiviral drugs. Entecavir sales and DDDs increased rapidly, while the use of Chuanhuning injection decreased significantly.
【作者单位】：华中科技大学同济医学院附属同济医院药学部;
【分类号】：R95

【参考文献】